CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.
Pembrolizumab (Keytruda, Merck) plus ramucirumab (Cyramza, Eli Lilly) extended OS compared with standard of care for individuals previously treated with chemotherapy and immunotherapy, results of the Lung-MAP Nonmatched Sub-Study S1800A showed.
This is the first trial of a second-line regimen with no chemotherapy backbone to suggest a potential survival benefit compared with